Officials, Health News, ET HealthWorld

NEW DELHI: Just two days before pharma major Pfizer announced withdrawal of its application for emergency use authorisation of its Covid-19 vaccine in India, an expert panel of the country’s drugs regulatory authority had recommended against granting such approval to the firm at this stage, officials said on Friday.

Pfizer on Friday said it has decided to withdraw its application for emergency use authorisation of its Covid-19 vaccine in India.

It was the first pharmaceutical firm to seek such an authorisation from the Drugs Controller General of India (DCGI) on December 5 for its Covid-19 vaccine, after it secured such clearance in the UK and Bahrain.

On February 3, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) deliberated on Pfizer’s application.

The firm presented its proposal for emergency use authorisation of Covid-19 mRNA Vaccine BNT162b before the committee, an official said.

“The committee

Read More